IP Library Granted Patent US 8,440,460
Granted Patent B2
US 8,440,460 · App. 11/996,732 · Granted May 14, 2013

Methods for transdifferentiating cells

Inventors: Zeev Estrov (Houston, TX); Gideon Strassmann (Naples, FL)
Assignees: The Board of Regents of the University of Texas System; Gideon Strassmann
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,440,460
App. No.
11/996,732
Granted
May 14, 2013
Kind
B2
Abstract

The present provides methods for affecting and/or altering the differentiation state of a cell. In certain embodiments, the present invention provides methods to transdifferentiate a cell into an endothelial cell or a hematopoietic cell. In the practice of the invention, a demethylating agent (e.g., 5-azacytidine) is used to affect and/or alter the differentiation state of a cell. The invention demonstrates the transdifferentiation of numerous cell types, including cell populations that are themselves somewhat differentiated (e.g., normal fibroblasts) into distinct cell types, including hematopoietic cells and endothelial cells, which transdifferentiation is effected further through the selection of particular growth factors which, together with the demethylating agents, directs the differentiation path. The invention provides a novel approach to providing useful cell types for many types of medical applications.

Claims (7)

1. A method of transdifferentiating fibroblasts of a bone marrow stromal cell into hematopoietic cells, the method comprising culturing said fibroblasts in a medium comprising a demethylating agent, granulocyte-macrophage stimulating factor (GM-CSF) and stem cell factor (SCF) in an amount and for a time effective to transdifferentiate said cells into hematopoietic cells, to provide a population of cells comprising said hematopoietic cells.

2. The method of claim 1 , wherein the demethylating agent is 5-azacytidine or 5-aza-2-deoxycytidine, zebularine, procaine, epigallocatechin-3-gallate, RG108, 1-β-D-arabinofuranosyl-5-azacytosine, dihydro-5-azacytidine or L-ethionine.

3. The method of claim 2 , wherein the demethylating agent is 5-azacytidine or 5-aza-2-deoxycytidine.

4. The method of claim 1 , wherein the cells are cultured in the medium comprising the demethylating agent for a period of time of from about 1 minute to about 1 week.

5. The method of claim 1 , wherein the demethylating agent is present in the medium at from about 0.1 μg/ml to about 10 μg/ml.

6. The method of claim 1 , further comprising administering cells of the cell population to a subject.

7. The method of claim 6 , wherein the subject is a human subject.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2008
From: ESTROV, ZEEV
To: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 020552/0921 →
Continuity (4)
Provisional Application 60702749 · Jul 27, 2005
Provisional Application 60729708 · Oct 24, 2005
Provisional Application 60734864 · Nov 9, 2005
Related Publication 20110206644A1 · Aug 25, 2011